Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 89 results for vte

  1. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued

  2. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153

  3. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (IPG554)

    Evidence-based recommendations on balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension in adults. This involves inserting and inflating a balloon in blocked blood vessels in the lungs to improve blood flow.

    Interventional procedures guidance
    Published
    27 April 2016
    View recommendations

    Sections for IPG554

  4. Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee (IPG317)

    Evidence-based recommendations on individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee. This involves inserting an individually designed implant at the knee between the thigh and shin bones to realign the knee and prevent bone-on-bone rubbing.

    Interventional procedures guidance
    Published
    23 September 2009
    View recommendations

    Sections for IPG317

  5. Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230)

    Evidence-based recommendations on arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis. This involves flushing the joint with fluid, which is introduced through small incisions in the knee.

    Interventional procedures guidance
    Published
    22 August 2007
    View recommendations

    Sections for IPG230

  6. Research into the long-term treatment effects of rivaroxaban is needed.

    Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Number TA287 Date issued June 2013 Other

    Research recommendation
    Published
    9 June 2015

  7. NICE considered that further research on the geko device in clinical settings could focus on reducing the current uncertainties about the reduction in relative risk in the defined patient population, and allow investigation into its use in broader patient populations.

    Comes from guidance The geko device for reducing the risk of venous thromboembolism Number MTG19 Date issued June 2014 Other

    Research recommendation
    Published
    9 June 2015

  8. There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for people who have cancer and experience an acute pulmonary embolism or deep vein thrombosis. As in NICE technology appraisal guidance 261 it is recommended that further research should be carried out.

    Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Number TA287 Date issued June 2013 Other

    Research recommendation
    Published
    9 June 2015

  9. More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee replacement would decrease the uncertainty of the clinical and cost effectiveness of these treatments. Trials directly comparing apixaban with rivaroxaban, dabigatran etexilate and fondaparinux would strengthen the evidence base for these comparisons.

    details Comes from guidance Apixaban for preventing venous thromboembolism after hip or knee replacement surgery Number TA245

    Research recommendation
    Published
    9 June 2015

  10. Early mobilisation and optimum positioning of people with acute stroke: How safe and effective is very early mobilisation delivered by appropriately trained healthcare professionals after stroke?

    on oxygenation and lead to a reduction in complications such as venous thromboembolism and hypostatic pneumonia. There could be benefits...

    Research recommendation
    Published
    11 May 2022

  11. Aspirin prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur:- What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?

    inexpensive. Source guidance details Comes from guidance Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep...

    Research recommendation
    Published
    15 November 2018

  12. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

    NICE guideline
    Published
    14 December 2023
    View recommendations

    Sections for NG238

  13. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    22 August 2012
    View recommendations

    Sections for TA263

  14. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

    Technology appraisal guidance
    Published
    22 May 2013
    View recommendations

    Sections for TA285

  15. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA322